Company Description
CNBX Pharmaceuticals Inc., a clinical stage company, engages in the discovery, development, and commercialization of novel cannabinoid-based products and technologies for the treatment of cancer.
Its lead product candidate is Cannabics SR, an oral capsule developed for the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome.
The company is also developing various drug candidates, including PLP-33 for the treatment of lateral spreading or sessile, and colorectal polyps during colonoscopy; BRST-33 to treat breast cancer; MLN-33 for the treatment of Melanoma; and PRST-33 to treat prostate cancer.
In addition, it is developing RCC-33, an oral capsule containing a formulation of cannabinoids for the treatment of colorectal cancer; and Cannabics CDx, an ex-vivo drug sensitivity test.
The company was formerly known as Cannabics Pharmaceuticals Inc. and changed its name to CNBX Pharmaceuticals Inc. in March 2022.
CNBX Pharmaceuticals Inc. was incorporated in 2004 and is based in Bethesda, Maryland. The company is a subsidiary of Cannabics Inc.
| Country | United States |
| Founded | 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2 |
| CEO | Eyal Barad |
Contact Details
Address: #3 Bethesda Metro Center, Suite 700 Bethesda, Maryland 20814 United States | |
| Phone | 877-424-2429 |
| Website | cnbxpharma.com |
Stock Details
| Ticker Symbol | CNBX |
| Exchange | OTCMKTS |
| Fiscal Year | September - August |
| Reporting Currency | USD |
| CIK Code | 0001343009 |
| CUSIP Number | 13764M100 |
| ISIN Number | US13764M2098 |
| Employer ID | 20-3373669 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Gabriel Yariv | President, Chief Operating Officer and Executive Chairman |
| Uri Ben-Or CPA, CPA, M.B.A., MBA | Chief Financial Officer |
| Eyal Barad | Co-Founder, Chief Executive Officer and Director |
| Dr. Sanja Goldberg | Chief Technology Officer |
| Noam Permont | Vice President of Public Relations and Investor Relations |
| Dr. Sigalit Ariely-Portnoy Ph.D. | Senior Advisor of Regulation, Validation and Quality and Member of Advisory Board |
| Dr. Tal Mofkadi Ph.D. | Financial Advisor and Member of Advisory Board |
| Yasha Borstein | Chief Data Officer |
| Dr. Yaakov Waksman | Head of Cannabidiol Research |
| Dr. Ilya Reznik M.D. | Head of Neuropsychiatry Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 16, 2024 | 10-Q | Quarterly Report |
| Apr 15, 2024 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| Mar 22, 2024 | 8-K | Current Report |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 12, 2024 | 10-Q | Quarterly Report |
| Nov 30, 2023 | 10-K | Annual Report |
| Jul 14, 2023 | 10-Q | Quarterly Report |
| Apr 14, 2023 | 10-Q | Quarterly Report |
| Mar 6, 2023 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 8, 2023 | 8-K | Current Report |